Remicade
What it is used for
Rheumatoid Arthritis in Adults: Remicade, in combination with methotrexate, is indicated for the reduction of signs and symptoms and prevention of structural joint damage (erosions and joint space narrowing) in: patients with active disease despite treatment with methotrexate; patients with active disease who have not previously received methotrexate. Remicade should be given in combination with methotrexate. Efficacy and safety in Rheumatoid Arthritis have been demonstrated only in combination with methotrexate. Ankylosing Spondylitis: Remicade is indicated for the reduction of signs and symptoms and improvement in physical function in patients with active disease. Psoriatic arthritis: Remicade is indicated for the treatment of the signs and symptoms, as well as for the improvement in physical function in adult patients with active and progressive psoriatic arthritis who have responded inadequately to disease-modifying anti-rheumatic drug (DMARD) therapy. Remicade may be administered in combination with methotrexate. Psoriasis: Remicade is indicated for the treatment of adult patients with moderate to severe plaque psoriasis for whom phototherapy or conventional systemic treatments have been inadequate or are inappropriate. Safety and efficacy beyond 12 months have not been established. Crohn’s Disease in Adults and in Children and adolescents (6-17 years): Remicade is indicated for the treatment of moderate to severe Crohn’s disease, to reduce the signs and symptoms and to induce and maintain clinical remission in patients who have an inadequate response to conventional therapies. Refractory Fistulising Crohn’s Disease: Remicade is indicated for reducing the number of draining enterocutaneous and rectovaginal fistulas and maintaining fistula closure in adult patients. Ulcerative colitis in Adults and in Children and adolescents (6 to 17 years); Remicade is indicated for the treatment of moderately severe to severe active ulcerative colitis in patients who have had an inadequate response to conventional therapy.
How to take it
The way to take this medicine is: Intravenous Infusion.
- Store at 2 to 8 degrees Celsius
- Shelf lifetime is 3 Years.
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems
How to take it
The way to take this medicine is: Intravenous Infusion.
- Store at 2 to 8 degrees Celsius
- Shelf lifetime is 3 Years.
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
Pregnant or planning a pregnancy?
For the active ingredient infliximab
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Do I need a prescription?
We are unable to tell you if you need a prescription for this medicine. You can ask your pharmacist.This medicine is
Visual appearance
White solid, with no evidence of meltback; free of foreign particles.
Is this medicine subsidised?
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on March 1, 2020. To learn more about this subsidy, visit the Pharmaceutical Benefits Scheme (PBS) website.